Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AFMD NASDAQ:BFRI NASDAQ:BON NASDAQ:MTEX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAFMDAffimed$0.18$0.25$0.07▼$1.13$2.92M2.0751.16 million shsN/ABFRIBiofrontera$0.98+13.3%$0.98$0.55▼$1.19$12.55M0.83344,241 shs287,089 shsBONBon Natural Life$1.32-2.3%$1.29$1.13▼$3.40$10.72M-0.1743,353 shs24,475 shsMTEXMannatech$5.88+6.9%$5.15$3.80▼$12.45$11.35M0.7124,918 shs3,280 shsBeginner's Guide To Retirement StocksClick the link to see MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAFMDAffimed0.00%0.00%0.00%0.00%0.00%BFRIBiofrontera0.00%-7.48%+8.14%-2.74%+31.27%BONBon Natural Life0.00%+8.00%+3.85%-8.78%-11.76%MTEXMannatech0.00%-3.51%+30.33%-16.67%-41.53%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAFMDAffimed$0.18$0.25$0.07▼$1.13$2.92M2.0751.16 million shsN/ABFRIBiofrontera$0.98+13.3%$0.98$0.55▼$1.19$12.55M0.83344,241 shs287,089 shsBONBon Natural Life$1.32-2.3%$1.29$1.13▼$3.40$10.72M-0.1743,353 shs24,475 shsMTEXMannatech$5.88+6.9%$5.15$3.80▼$12.45$11.35M0.7124,918 shs3,280 shsBeginner's Guide To Retirement StocksClick the link to see MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAFMDAffimed0.00%0.00%0.00%0.00%0.00%BFRIBiofrontera0.00%-7.48%+8.14%-2.74%+31.27%BONBon Natural Life0.00%+8.00%+3.85%-8.78%-11.76%MTEXMannatech0.00%-3.51%+30.33%-16.67%-41.53%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAFMDAffimed 0.00N/AN/AN/ABFRIBiofrontera 2.00HoldN/AN/ABONBon Natural Life 1.00SellN/AN/AMTEXMannatech 1.00SellN/AN/ACurrent Analyst Ratings BreakdownLatest AFMD, BON, BFRI, and MTEX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/11/2026MTEXMannatech Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)6/1/2026BFRIBiofrontera Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)5/26/2026MTEXMannatech Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)5/14/2026BFRIBiofrontera Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)4/27/2026BFRIBiofrontera Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)(Data available from 6/15/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAFMDAffimed$877K3.33N/AN/A$4.19 per share0.04BFRIBiofrontera$43.20M0.27N/AN/A$0.90 per share1.02BONBon Natural Life$18.67M0.57N/AN/A$7.13 per share0.18MTEXMannatech$108.04M0.10N/AN/A($2.75) per share-2.07Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAFMDAffimed-$114.66MN/AN/AN/AN/A-7,836.26%-193.84%-107.24%N/ABFRIBiofrontera-$10.54M-$0.97N/A15.25N/A-25.66%-515.34%-53.91%8/12/2026 (Estimated)BONBon Natural Life-$2MN/AN/AN/AN/AN/AN/AN/AN/AMTEXMannatech-$15.21M-$6.71N/AN/AN/A-11.97%-2,383.34%-40.24%N/ALatest AFMD, BON, BFRI, and MTEX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2026Q1 2026BFRIBiofrontera-$0.1150-$0.41-$0.2950-$0.41$10.25 million$10.08 million5/14/2026Q4 2025MTEXMannatechN/A$0.49N/A$0.49N/A$24.92 million4/15/2026Q4 2025MTEXMannatechN/A-$5.94N/A-$5.94N/A$26.64 million3/19/2026Q4 2025BFRIBiofrontera$0.29$0.50+$0.21$0.47$16.15 million$17.10 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthAFMDAffimedN/AN/AN/AN/AN/ABFRIBiofronteraN/AN/AN/AN/AN/ABONBon Natural LifeN/AN/AN/AN/AN/AMTEXMannatechN/AN/A-100.00%N/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAFMDAffimed0.131.931.93BFRIBiofrontera0.781.201.09BONBon Natural Life0.011.741.61MTEXMannatech0.481.090.59Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAFMDAffimed30.82%BFRIBiofrontera10.08%BONBon Natural Life0.57%MTEXMannatech12.98%Insider OwnershipCompanyInsider OwnershipAFMDAffimed3.80%BFRIBiofrontera4.80%BONBon Natural Life26.48%MTEXMannatech41.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAFMDAffimed20016.10 million15.49 millionNo DataBFRIBiofrontera7012.80 million11.77 millionNo DataBONBon Natural Life1008.13 million5.98 millionN/AMTEXMannatech2501.93 million1.13 millionNot OptionableAFMD, BON, BFRI, and MTEX HeadlinesRecent News About These CompaniesMannatech Announces Appointment of Yasir Haider as Chief Financial OfficerJune 8, 2026 | globenewswire.comMannatech (NASDAQ:MTEX) Share Price Crosses Below 200 Day Moving Average - Time to Sell?June 6, 2026 | americanbankingnews.comMannatech, Incorporated Announces Successful Approval of All Proposals at Annual Shareholder MeetingJune 3, 2026 | quiverquant.comQMannatech Announces Results of Annual Shareholders' MeetingJune 3, 2026 | globenewswire.comInsider Buying: Mannatech (NASDAQ:MTEX) Director Acquires 2,803 Shares of StockMay 22, 2026 | insidertrades.comInsider Buying: Mannatech (NASDAQ:MTEX) Director Acquires 5,000 Shares of StockMay 21, 2026 | insidertrades.comMannatech Stock Price HistoryMay 20, 2026 | investing.comMannatech Reports Financial Results for First Quarter 2026May 14, 2026 | globenewswire.comMannatech Reports Financial Results for Fourth Quarter and Year Ended 2025April 17, 2026 | markets.businessinsider.comMannatech, Incorporated Reports Financial Results for Fourth Quarter and Year Ended 2025April 17, 2026 | quiverquant.comQMannatech Reports Financial Results for Fourth Quarter and Year Ended 2025April 17, 2026 | globenewswire.comMannatech, IncorporatedApril 8, 2026 | edition.cnn.comMannatech Delays 10-K Filing Amid Going-Concern ReviewApril 2, 2026 | tipranks.comMannatech Announces Notification of Late FilingApril 1, 2026 | markets.businessinsider.comMannatech Inc. Reports Improved Quarterly Earnings Amid Sales DeclineNovember 13, 2025 | msn.comMannatech Reports Financial Results for Third Quarter 2025November 12, 2025 | globenewswire.comMicro-Cap Mannatech Stock Draws Frenzied Retail Buzz As Traders Pounce On 'Tiny Float' PlayOctober 13, 2025 | msn.comMannatech Extends Loan Repayment to March 2027September 12, 2025 | tipranks.comMannatech trading halted, volatility trading pauseAugust 14, 2025 | msn.comMannatech Reports Financial Results for Second Quarter 2025August 12, 2025 | businesswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesSpaceX Gets the Attention, But These 4 Stocks Could Get the ReturnsBy Bridget Bennett | May 25, 20265 Stocks Winning the AI Race While Everyone Watches NVIDIABy Bridget Bennett | May 26, 2026The Smart Glasses Gold Rush Is Leaving Old-School Eyewear BehindBy Jeffrey Neal Johnson | May 24, 20263 Space Infrastructure Stocks Gaining Momentum Ahead of the SpaceX IPOBy Ryan Hasson | May 20, 20263 Long-Duration Treasury ETFs to Watch if Rates FallBy Nathan Reiff | June 15, 2026AFMD, BON, BFRI, and MTEX Company DescriptionsAffimed NASDAQ:AFMDAffimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States and Germany. The company's lead product candidates include AFM13 that has completed Phase 2 clinical trial for CD30-positive lymphoma, Phase Ib clinical trial for hodgkin lymphoma, and completed Phase IIb clinical study for peripheral T-cell lymphoma; AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, which is in Phase IIa clinical trial for the treatment of advanced cancers; and AFM28, an innate cell engager (ICE), which is in preclinical development for the treatment acute myeloid. It develops AFM32, an ICE candidate that is in preclinical development for the treatment of solid tumors. It has collaboration with Artiva Biotherapeutics to develop the combination of acimtamig and AlloNK; license and strategic collaboration agreement with Roivant Sciences Ltd. to develop and commercialize novel ICE molecules, including AFM32, in oncology; and strategic collaboration agreement with Genentech for the development of certain product candidates, which includes novel NK cell engager-based immunotherapeutics to treat multiple cancers. The company was formerly known as Affimed Therapeutics B.V. and changed its name to Affimed N.V. in October 2014. Affimed N.V. was founded in 2000 and is headquartered in Mannheim, Germany.Biofrontera NASDAQ:BFRI$0.98 +0.11 (+13.28%) As of 02:18 PM Eastern This is a fair market value price provided by Massive. Learn more.Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's products are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions, as well as impetigo, a bacterial skin infection. It offers Ameluz, a prescription drug for use in combination with the RhodoLED lamp series, for photodynamic therapy for the lesion-directed and field-directed treatment of actinic keratosis of mild-to-moderate severity on the face and scalp. The company also provides Xepi, a topical non-fluorinated quinolone that inhibits bacterial growth for the treatment of impetigo. The company was incorporated in 2015 and is headquartered in Woburn, Massachusetts.Bon Natural Life NASDAQ:BON$1.32 -0.03 (-2.30%) As of 02:16 PM Eastern This is a fair market value price provided by Massive. Learn more.Bon Natural Life Limited, together with its subsidiaries, engages in the research and development, manufacture, and sale of functional active ingredients extracted from natural herb plants in the People's Republic of China and internationally. The company provides personal care ingredients, such as plant extracted fragrance compounds to perfume and fragrance manufacturers; natural health supplements comprising powder drinks and bioactive food ingredient products primarily used as food additives; and nutritional supplements. Its products are principally used by manufacturer customers in the functional food, personal care, cosmetic, and pharmaceutical industries. The company was founded in 2006 and is headquartered in Grand Cayman, the Cayman Islands.Mannatech NASDAQ:MTEX$5.88 +0.38 (+6.91%) As of 02:00 PM EasternMannatech, Incorporated operates as a health and wellness company in the Americas, Europe, the Middle East, Africa, and the Asia-Pacific. The company develops, markets, and sells nutritional supplements; topical and skin care, and anti-aging products; and weight-management and fitness products. It primarily sells its products directly, as well as through e-commerce and network marketing channels. Mannatech, Incorporated was incorporated in 1993 and is headquartered in Flower Mound, Texas. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas What's Behind the Social Media Controversy Surrounding IonQ? Mission Control: Floating In SpaceX's Record-Breaking Orbit 3 Dividend Increases Investors Can Actually Trust RH’s Strong Q1 Still Leaves Investors With One Big Question SpaceX Rings the Bell and Shatters Every Record Adobe Stock Just Got Cheaper—Is Wall Street Missing the Story? Alphabet's Most Overlooked Division Just Had a Big Week Robinhood Wants a Bigger Role in IPOs—Here's Why It Matters Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
